

Volume 33 · Issue 2 · June 2023

Psychiatry *and* Clinical Psychopharmacology



EISSN 2475-0581

psychiatry-psycho pharmacology.com

Editor in Chief

Mesut Çetin

Emeritus Professor of GATA Haydarpaşa Training Hospital, Istanbul, Turkey

Deputy Editor

Feyza Arıcıoğlu

Marmara University, Istanbul, Turkey

Section Editors

Glen Baker

University of Alberta, Edmonton, Canada

Altay Burak Dalan

Yeditepe University, Istanbul, Turkey

Rasim Somer Diler

University of Pittsburgh, Pittsburgh, USA

Serdar Dursun

University of Alberta, Edmonton, Canada

Andrew Greenshaw

University of Alberta, Edmonton, Canada

Marek Kubicki

Harvard Medical School, Boston, USA

Mihriban Heval Özgen

LUMC, Leiden University, Leiden, The Netherlands

Anita Riecher-Rössler

University of Basel, Basel, Switzerland

Gianluca Serafini

Department of Neuroscience, San Martino Hospital (IRCCS), Genoa, Italy

Bayram Yilmaz

Yeditepe University, Istanbul, Turkey

Associate Editors

Ömer Aydemir

Department of Psychiatry, Celal Bayar University School of Medicine, Manisa, Turkey

Leslie Citrome

New York Medical College, New York, USA

Yuan-Hwa Chou

Veterans General Hospital, Taipei, Taiwan

Christoph U. Correll

Charité University Medicine, Berlin, Germany

Ted Dinan

University College Cork, Dublin, Ireland

Cüneyt Evren

Department of Psychology, İstanbul Gelişim University, İstanbul, Turkey

Vahdet Görmez

Medeniyet University, İstanbul, Turkey

Kyooseob Ha

National University College of Medicine, Seoul, South Korea

Angelos Halaris

Loyola University, Chicago, USA

Jaime Eduardo Hallak

University of São Paulo, São Paulo, Brazil

Kenji Hashimoto

Chiba University Center for Forensic Mental Health, Division of Clinical Neuroscience, Chiba, Japan

Carsten Hjorthøj

Copenhagen Research Center for Mental Health, Copenhagen, Denmark

Hans W Hoek

University Medical Center Groningen, Groningen, The Netherlands

Matcheri Keshavan

Harvard Medical School, Boston, USA

Yong-Ku Kim

College of Medicine, Korea University, Seoul, South Korea

Brian Leonard

Emeritus Professor, National University, Galway, Ireland

Mingli Li

Sichuan University, Sichuan, China

Tao Li

Sichuan University, Sichuan, China

Xin Min Li

Alberta University, Edmonton, Canada

Qing Ma

University at Buffalo, Buffalo, USA

Norbert Muller

Ludwig-Maximilian-University, Munich, Germany

Kerim Munir

Harvard Medical School, Boston, USA

David Osser

Harvard Medical School, Boston, USA

Dost Öngür

Harvard Medical School, Boston, USA

Vedat Şar

Department of Psychiatry, Koç University School of Medicine, İstanbul, Turkey

Lut Tamam

Department of Psychiatry, Çukurova University School of Medicine, Adana, Turkey

Paul Thompson

University of Southern California, USA

Ali Evren Tufan

Department of Child and Adolescent Psychiatry, Abant İzzet Baysal University, School of Medicine, Bolu, Turkey

Erdem Tüzün

Department of Neuroscience, İstanbul University, Aziz Sancar Institute of Experimental Medicine, İstanbul, Turkey

Willem van den Brink

Amsterdam University Medical Centers, Amsterdam, The Netherlands

Allan Young

King's College, London, UK

Editorial Board

Adam Abba-Aji

University of Alberta, Edmonton, Canada

Yasser Ad-Dab'bagh

King Fahad Specialist Hospital, Dammam, Saudi Arabia

Mohammad Saleh Alghamdi

University of Alberta, Edmonton, Canada

José Alexandre de Souza Crippa

University of São Paulo, São Paulo, Brazil

Rafael Guimarães dos Santos

University of São Paulo, São Paulo, Brazil

Onur Burak Dursun

Republic of Turkey, Ministry of Health, Ankara, Turkey

Sugai Liang

Sichuan University, Sichuan, China

Yuping Ning

Guangzhou Brain Hospital, Guangzhou, China

David Nutt

Imperial College, London, UK

Jim Van Os

Utrecht University Medical Centre, Utrecht, The Netherlands

Mücahit Öztürk

Ibn Haldun University, İstanbul, Turkey

Kemal Sayar

Marmara University, İstanbul, Turkey

Carol Tamminga

UT Southwestern Medical Center, Dallas, USA

Massimo Tusconi

University of Cagliari, Cagliari, Italy

Patricia Zunszain

King's College, London, UK

Ethics Editor

Şefik Görkey

Koç University, School of Medicine, Department of Medical History and Ethics, İstanbul, Turkey

Biostatistics Editor

Arzu Baygül

Koç University, İstanbul, Turkey

İlker Ercan

Uludağ University, School of Medicine, Department of Biostatistics, Bursa, Turkey



Founder
İbrahim KARA

General Manager
Ali ŞAHİN

Finance Coordinator
ElifYILDIZ ÇELİK

Journal Managers
İrem SOYSAL
Deniz KAYA
İrmak BERBEROĞLU
ARZU ARI

Publication Coordinators
Gökhan ÇİMEN
Alara ERGİN
İrem ÖZMEN
Derya AZER

Burcu DEMİRER
Beyza HİMMETOĞLU DAL

Project Coordinators
Doğan ORUÇ
Sinem Fehime KOZ

Contact

Address: Büyükdere Cad. 199/6,
34394, Şişli, İstanbul, Türkiye
Phone: +90 212 217 17 00
E-mail: info@avesyayincilik.com

About the Psychiatry and Clinical Psychopharmacology

Psychiatry and Clinical Psychopharmacology is a peer reviewed, open access, online-only journal.

Psychiatry and Clinical Psychopharmacology is a quarterly journal that is published in English in March, June, September, and December. Psychiatry and Clinical Psychopharmacology is supported by the Turkish Association for Psychopharmacology.

Journal History

As of 2016, the journal has changed its title to Psychiatry and Clinical Psychopharmacology.

Current Title (2017 - ...)

Psychiatry and Clinical Psychopharmacology

EISSN: 2475-0581

Previous Title (1990-2017)

Klinik Psikofarmakoloji Bülteni – Bulletin of Clinical Psychopharmacology

ISSN: 1302-9657

EISSN: 1302-9657

Abstracting and Indexing

Psychiatry and Clinical Psychopharmacology is covered in the following abstracting and indexing databases;

- Science Citation Index Expanded
- Scopus
- DOAJ
- Embase
- Gale
- CNKI
- HINARI
- Proquest: Proquest Psychology Journals
- Proquest Health&Medical Complete
- EBSCO
- Chemical Abstracts (CAS)
- TUBITAK ULAKBIM TR Index

All content published in the journal is permanently archived in Portico.

Aims, Scope, and Audience

Psychiatry and Clinical Psychopharmacology aims to publish studies of the highest scientific and clinical value, and encourages the submission of high-quality research that advances the understanding scientific fields such as psychiatry, child and adolescent psychiatry, neuroscience, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences.

Psychiatry and Clinical Psychopharmacology covers a wide range of topics related to psychiatry and clinical psychopharmacology as well as forming a scientific forum by producing quality debate on various disciplines. The journal is interested in publishing original research that addresses important clinical questions and advances the understanding and treatment of these conditions. This may include studies on psychiatry, child and adolescent psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences.

Psychiatry and Clinical Psychopharmacology publishes original research, reviews, case reports, letters to the editors, editorials, and short communications/brief reports within its scope. Conference proceedings may also be considered for publication.

The target audience of the journal includes specialists, residents, and scientists in psychiatry, psychology, neurology, neuroscience, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related disciplines.

Open Access Policy

Psychiatry and Clinical Psychopharmacology is an open access publication.

Starting on March 2021, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International License which allows third parties to read and share the material immediately upon publication for only non-commercial purposes by giving the appropriate credit to the original work. Adaptation and modification of the material is not permitted.

The content published before March 2021 was licensed under a traditional copyright, but the archive is still available for free access.

All published content is available online, free of charge at <https://psychiatry-psychopharmacology.com/>.

Authors retain unrestricted copyrights and publishing rights in Psychiatry and Clinical Psychopharmacology.

When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Copyright Policy

A Copyright Agreement and Acknowledgement of Authorship form should be submitted with all manuscripts. By signing this form, authors agree that the article, if accepted for publication by the Psychiatry and Clinical Psychopharmacology, will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC 4.0) which allows third parties to read and share the material immediately upon publication for only non-commercial purposes by giving the appropriate credit to the original work. Adaptation and modification of the material is not permitted.

When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Authors retain unrestricted copyrights and publishing rights in Psychiatry and Clinical Psychopharmacology.

Publication Fee Policy

Psychiatry and Clinical Psychopharmacology is funded by article processing charges (APC).

The article processing charge for the journal is 590 USD (updated in February 2021). Apart from the APC, there are no other fees or surcharges associated with the evaluation or publication process.

Authors are required to properly disclose any financial support they receive for the payment of the article processing charge.

Disclaimer

The statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the views of the editors, editorial board, and/or publisher. The editors, editorial board, and publisher are not responsible for the content of the manuscripts and do not necessarily endorse the views expressed in them. It is the responsibility of the authors to ensure that their work is accurate and well-researched, and the views expressed in their manuscripts are their own. The editors, editorial board, and publisher simply provide a platform for the authors to share their work with the scientific community.

You can find the current version of the Instructions to Authors at: <https://psychiatry-psychopharmacology.com/en/instructions-to-authors-1020>

Editor in Chief: Mesut Cetin, M.D., Professor of Psychiatry

Address: Bagdat Caddesi Birgen Plaza 226/7 Kadikoy 34728 Istanbul, Turkey

Mobile & Whatsapp: +90-532-272-3252
psikofarmakoloji@gmail.com

Publisher: AVES

Address: Büyükdere Cad. 199/6, 34394, Şişli, İstanbul, Türkiye

Phone: +90 212 217 17 00

E-mail address: info@avesyayincilik.com

www.avesyayincilik.com

CONTENTS

ORIGINAL ARTICLES

- 70 The Development of Psychosis in Patients with Substance Use Disorder and Its Association with Cavum Septum Pellucidum and Adhesio Interthalamica**
Ceylan Ergül, Cumali Aydın, Bahruz Shukurov, Celal Şalçini, Necati Alp Tabak, Nesrin Dilbaz
- 76 The Association Between Clozapine Plasma Concentration, CYP2D6 (*10, *2) Polymorphisms and Risk of Adverse Reactions**
Kankan Qu, Qin Zhou, Haohao Zhu, Zhenhe Zhou, Yuan Shen, Lin Tian, Xujiang Su
- 84 Evaluation of Serum Complement Levels and Factors Affecting Treatment Resistance in Patients with Schizophrenia**
Mustafa Goker, Hasan Mervan Aytac, Oya Guclu
- 94 Mechanisms in Emotional Information Processing in Individuals with Major Depressive Disorder: An Event-Related Potential Study of an Information Processing Model**
Daniel Kwasi Ahorsu, Ken Ho Ming Chung, Ho Hon Wong, Michael Gar Chung Yiu, Yat Fung Mok, Ka Shun Lei, Hector Wing Hong Tsang
- 108 The Relationship Between Depression, Anxiety and Stress Levels on Suicidal Behavior in Patients with Schizophrenia**
Şafak Taktak, Hilal Seki Öz
- 117 Life Chart of Substance Use Career: A Clinical Profile Study from Turkey**
Cavid Guliyev, Melike Simsek, Sevinc Bezek-Dino, Kultegin Ogel
- 126 The Relationship Between Suicidal Behavior, Neurocognitive Functions, and Insight in Patients with Schizophrenia**
Suneyye Yasemin Calli, Yağmur Sever Fidan, Engin Emrem Bestepe, Filiz Izci
- 134 Turkish Adaptation, Validity, and Reliability Study of Shitsu-Taikan-Sho (Alexisomia) Scale**
Muhammed Hakan Aksu, Nur Nihal Baltacı, İrem Ekmekçi Ertek, Behcet Coşar

CASE REPORT

- 143 Safe and Effective Use of Low-Dose Clozapine for Tardive Dyskinesia in a Patient with Schizophrenia and Comorbid Epilepsy: A Case Report**
Mahmut Selçuk

REVIEW

- 147 Resveratrol in Neurodegeneration, in Neurodegenerative Diseases, and in the Redox Biology of the Mitochondria**
Betül Danışman, Sevim Ercan Kelek, Mutay Aslan